Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Financing Activities (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Cash from Financing Activities readings, the most recent being $3.0 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 1280.4% to $3.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $19.3 million, a 44.69% decrease, with the full-year FY2025 number at $16.1 million, down 72.85% from a year prior.
  • Cash from Financing Activities hit $3.0 million in Q1 2026 for Atara Biotherapeutics, up from -$3000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $35.8 million in Q3 2024 to a low of -$328000.0 in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was $1.0 million (2025), compared with a mean of $7.8 million.
  • The widest YoY moves for Cash from Financing Activities: up 17308.17% in 2024, down 168.79% in 2024.
  • Atara Biotherapeutics' Cash from Financing Activities stood at $32.3 million in 2022, then plummeted by 95.32% to $1.5 million in 2023, then tumbled by 121.69% to -$328000.0 in 2024, then surged by 99.09% to -$3000.0 in 2025, then surged by 98466.67% to $3.0 million in 2026.
  • The last three reported values for Cash from Financing Activities were $3.0 million (Q1 2026), -$3000.0 (Q4 2025), and $1.0 million (Q3 2025) per Business Quant data.